0001875091 2026-01-01 2026-06-30 0001875091 srt:ScenarioForecastMember 2026-09-23 2026-09-23 0001875091 srt:ScenarioForecastMember srt:BoardOfDirectorsChairmanMember 2026-09-23 2026-09-23 0001875091 srt:ScenarioForecastMember us-gaap:CommonStockMember 2026-09-14 0001875091 srt:ScenarioForecastMember 2026-09-14 2026-09-14 0001875091 2025-01-01 2025-06-30 0001875091 nrsn:GeneralAndAdministrativeExpensesMember 2025-01-01 2025-06-30 0001875091 nrsn:GeneralAndAdministrativeExpensesMember 2026-01-01 2026-06-30 0001875091 nrsn:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-06-30 0001875091 nrsn:ResearchAndDevelopmentExpensesMember 2026-01-01 2026-06-30 0001875091 2026-03-26 2026-03-26 0001875091 us-gaap:RestrictedStockUnitsRSUMember 2026-03-26 2026-03-26 0001875091 nrsn:SeveralEmployeesMember 2026-03-26 2026-03-26 0001875091 nrsn:SeveralEmployeesMember 2026-02-23 2026-02-23 0001875091 2026-01-07 2026-01-07 0001875091 nrsn:SeveralEmployeesMember 2026-01-07 2026-01-07 0001875091 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-07-01 2026-07-31 0001875091 us-gaap:CommonStockMember 2026-06-01 2026-06-30 0001875091 us-gaap:CommonStockMember 2026-04-01 2026-04-30 0001875091 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001875091 nrsn:AprilTwoThousandTwentyFourPurchaseAgrementMember 2024-03-10 2024-03-10 0001875091 us-gaap:CommonStockMember 2026-02-28 0001875091 nrsn:PrefundedWarrantsMember 2026-02-28 0001875091 us-gaap:CommonStockMember nrsn:SalesAgreementMember 2026-01-01 2026-06-30 0001875091 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001875091 2026-04-02 0001875091 2025-06-30 0001875091 2026-06-30 0001875091 2024-12-31 0001875091 2025-12-31 0001875091 us-gaap:RetainedEarningsMember 2025-06-30 0001875091 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001875091 us-gaap:CommonStockMember 2025-06-30 0001875091 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001875091 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001875091 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001875091 us-gaap:RetainedEarningsMember 2024-12-31 0001875091 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001875091 us-gaap:CommonStockMember 2024-12-31 0001875091 us-gaap:RetainedEarningsMember 2026-06-30 0001875091 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001875091 us-gaap:CommonStockMember 2026-06-30 0001875091 us-gaap:RetainedEarningsMember 2026-01-01 2026-06-30 0001875091 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-06-30 0001875091 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001875091 us-gaap:RetainedEarningsMember 2025-12-31 0001875091 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001875091 us-gaap:CommonStockMember 2025-12-31 shares iso4217:USD iso4217:USD shares false 2026-06-30 Q2 0001875091 --12-31 6-K 2026 001-41084 NeuroSense Therapeutics Ltd.

231000

166000

540000

565000

73000

47000

844000

778000

52000

58000

170000

22000

52000

250000

896000

1028000

729000

799000

2270000

1717000

2999000

2516000

72000

2999000

2588000

200000000

90000000

1836154

1627859

49245000

46225000

-51348000

-47785000

-2103000

-1560000

896000

1028000

599000

602000

2102000

2503000

1345000

2189000

-3447000

-4692000

-116000

-17000

-3563000

-4709000

-2.1

-3.7

1731255

1270132

1627859

46225000

-47785000

-1560000

120483

2066000

14814

72998

954000

-3563000

1836154

49245000

-51348000

-2103000

1161447

39243000

-36660000

2583000

44198

1288000

9700 13000 13000

14776

306000

-4709000

1230121

40850000

-41369000

-519000

-3563000

-4709000

8000

899000

306000

-5000

170000 42000

-170000

-33000

-25000

-141000

-15000

-67000

651000

312000

-1990000

-4000000

4000

8000

2000

5000

-6000

-13000

13000

2112000

1353000

46000

65000

2066000

1301000

-5000

65000

-2712000

166000

3378000

231000

666000

55000

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><span style="font-weight: bold;">Note 1 — General</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><span style="font-weight: bold;"> </span></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"> <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><span style="font-weight: bold;">A.</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">NeuroSense Therapeutics Ltd. (“NeuroSense” or the “Company”) was incorporated in Israel on February 13, 2017. NeuroSense is a clinical-stage pharmaceutical company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. The Company’s lead product candidate, PrimeC, is a novel oral formulation of a fixed dose combination composed of a specific ratio and doses of two FDA-approved drugs.</span></td> </tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer’s disease and Parkinson’s disease, with a similar strategy of combined products.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The Company’s ordinary shares and warrants began trading on the Nasdaq Capital Market on December 9, 2021 under the ticker symbols “NRSN” and “NRSNW,” respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><span style="font-weight: bold;"> </span></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"> <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><span style="font-weight: bold;">B.</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The Company currently has no products approved for sale, and the Company’s operations have been funded primarily by its shareholders. To date, the Company has generated no sales or revenues, has incurred negative networks capital and also losses and expects to incur significant additional losses due to the continuing focus on the research, development, clinical activities of its product candidates, preclinical programs, business development, organizational structure and to advance the programs within the Company’s pipeline. Consequently, its operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds.</span></td> </tr></tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Based on current expected level of operating expenditures, the Company’s cash resources as at June 30, 2026 shall not be sufficient to fund the Company’s operations for a period of 12 months from the approval of these consolidated interim financial statements, assuming that the Company will continue its development plan in accordance with the original pipeline and without delaying or slowing down the progress of its plans. The Company will require additional cash to fund the execution of its mid and long-term development program. The Company anticipates raising additional funds through public or private sales of debt or equity securities, collaborative arrangements, or some combination thereof. Whilst management is progressing with its plans to secure external financing, these still require approval by third parties, and accordingly, there is no assurance that any such arrangement will be entered into or that financing will be available when needed in order to allow it to continue its operations, or if available, on terms favorable or acceptable to it.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">These consolidated financial statements have been prepared in accordance with US generally accepted accounting principles (GAAP) assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. In the event financing is not obtained, the Company may pursue cost cutting measures or may be required to delay, reduce the scope of, or eliminate any of its development programs or clinical trials, these events could have a material adverse effect on its business. These factors raise substantial doubt about the Company ability to continue as a going concern. The consolidated interim financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company were unable to continue as a going concern.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In addition, in light of our limited cash resources and ongoing capital requirements, in June 2026 the Company implemented cost-reduction measures, including a reduction in workforce and other reductions in operating expenses. The Company continues to evaluate additional financing opportunities and strategic alternatives to support its operations and the continued development of PrimeC and our other product candidates. See also Note 5 in respect to share-based settlements of obligations to service providers for past and future services.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><span style="font-weight: bold;"> </span></span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"> <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><span style="font-weight: bold;">D.</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Since October 2023, Israel has experienced ongoing regional hostilities involving Hamas, Hezbollah, Iran and other regional actors. During 2026, regional tensions further escalated, including renewed military hostilities involving Israel, Iran and other regional actors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of the date of approval of these consolidated financial statements, these developments have not had a material adverse effect on the Company’s business or operations, and its clinical and business development activities continue as planned. The Company continues to monitor the situation, and any further escalation or deterioration in the security situation could adversely affect its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p></td> </tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><span style="font-weight: bold;">E.</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify;"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The Company is required to comply with the continued listing requirements of The Nasdaq Capital Market, including requirements relating to the minimum bid price of its ordinary shares and its market value of listed securities (“MVLS”). The Company previously experienced periods of non-compliance with certain Nasdaq continued listing requirements and subsequently regained compliance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On April 2, 2026, the Company received notification letters from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share, and the applicable MVLS requirement, as the closing bid price of the Company’s ordinary shares and its MVLS had remained below the required thresholds for 30 consecutive business days. The Company was provided until September 29, 2026 to regain compliance with these requirements. The Company is pursuing measures intended to regain compliance; however, there can be no assurance that it will regain compliance within the applicable compliance period or at all. Failure to regain compliance could result in the delisting of the Company’s ordinary shares from Nasdaq and could adversely affect the liquidity and market price of the Company’s ordinary shares and its ability to raise additional capital.</span></p></td> </tr></tbody> </table>

2017-02-13 1 P30D

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><span style="font-weight: bold;">Recently issued accounting pronouncements, not yet adopted</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In December 2025, the FASB issued ASU 2025-11, Interim Reporting, Narrow-Scope Improvements. The ASU was updated to improve the navigability of the required interim disclosures within ASC 270 and to clarify when the guidance applies. This ASU is not intended to change the fundamental nature of interim reporting or expand or reduce current interim disclosure requirements. ASU 2025-11 is effective for fiscal years beginning after December 15, 2027, including interim periods within those fiscal years, with early adoption permitted. Upon adoption, the guidance can be applied prospectively or retrospectively. The Company is currently evaluating the effect of adopting the ASU on its condensed consolidated financial statement disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><span style="font-weight: bold;">Note 3 - Shareholders’ Equity</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"> <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">a.</span></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the six months ended June 30, 2026, the Company sold 94,858 of its ordinary shares pursuant to the Sales Agreement for aggregate net proceeds of approximately $1,456 thousand.</span></td> </tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"> <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">b.</span></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During February 2026, 13,814 pre-funded warrants were exercised into 13,814 ordinary shares of the Company. Following this exercise there are no more unexercised pre-funded warrants.</span></td> </tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"> <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">c.</span></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On March 10, 2026, the Company’s shareholders approved an amendment to the Company’s articles of association to increase the registered share capital of the Company by an additional 110,000,000 ordinary shares, such that the total registered share capital of the Company would consist of 200,000,000 ordinary shares, no par value per share.</span></td> </tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"> <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">d.</span></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">During the six month period ended June 30, 2026, the Company issued 1,000 ordinary shares following vested RSUs.</span></td> </tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"> <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">e.</span></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In April 2026, the Company entered into a private placement transaction with certain Company’s executive officers and shareholders, according to which the Company agreed to issue 38,125 of its ordinary shares for total consideration of $610 thousands. 25,625 ordinary shares were issued in June 2026 and 12,500 shares issued in July 2026.</span></td> </tr></tbody> </table>

94858

1456000

13814

110000000

200000000

1000

38125

610000

25625

12500

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><span style="font-weight: bold;">Note 4 - Share Based Payment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><span style="font-weight: bold;"> </span></span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"> <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">a.</span></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On January 7, 2026, the Company’s board of directors approved the grant of an aggregate amount of 12,998 restricted shares to several service providers for services received. The fair value was estimated at the amount of $223 thousand.</span></td> </tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"> <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">b.</span></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On February 23, 2026, the Company issued 3,000 restricted shares to a service provider for his past services.</span></td> </tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"> <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top;"><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">c.</span></td> <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On March 26, 2026, the Company’s board of directors approved the grant of an aggregate amount of 57,000 restricted shares to several employees and officers. The restricted shares vest on a quarterly basis over two years. The aggregate fair value was estimated at the amount of $878 thousand.</span></td> </tr></tbody> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The share-based expense recognized in the statements of operations were as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"> <tbody><tr style="vertical-align: bottom;"><td> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">June 30,</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> </tr><tr style="vertical-align: bottom;"><td> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> </tr><tr style="vertical-align: bottom;"><td> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">U.S dollars in thousands</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="width: 76%; text-align: left;">Share-based compensation expense - Research and development</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">768</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">18</td> <td style="width: 1%; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: left; padding-bottom: 1.5pt;">Share-based compensation expense - General and administrative</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">131</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">288</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right;">899</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right;">306</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> </tr></tbody></table>

12998

223000

3000

57000

P2Y

878000

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The share-based expense recognized in the statements of operations were as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt;"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"> <tbody><tr style="vertical-align: bottom;"><td> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">June 30,</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> </tr><tr style="vertical-align: bottom;"><td> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">2026</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">2025</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> </tr><tr style="vertical-align: bottom;"><td> </td> <td style="font-weight: bold; padding-bottom: 1.5pt;"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;">U.S dollars in thousands</td> <td style="padding-bottom: 1.5pt; font-weight: bold;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="width: 76%; text-align: left;">Share-based compensation expense - Research and development</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">768</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">18</td> <td style="width: 1%; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: White;"> <td style="text-align: left; padding-bottom: 1.5pt;">Share-based compensation expense - General and administrative</td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">131</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> <td style="padding-bottom: 1.5pt;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left;"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: right;">288</td> <td style="padding-bottom: 1.5pt; text-align: left;"> </td> </tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255);"> <td style="padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right;">899</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right;">306</td> <td style="padding-bottom: 2.5pt; text-align: left;"> </td> </tr></tbody></table>

768000

18000

131000

288000

899000

306000

one-for-20

158117

84000

Less than $1 thousand. Including balance with related parties at the amount of $599 thousand and $602 thousand as of June 30, 2026 and December 31, 2025, respectively. After giving effect to the reverse share split, see also note 5. After giving effect to the reverse share splits, see also note 5. After giving effect to the share splits and the reverse share splits, see also note 5. less than 1 thousands.